These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9218858)

  • 41. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
    Lazzaroni M; Bargiggia S; Bianchi Porro G
    Am J Gastroenterol; 1997 Apr; 92(4):649-52. PubMed ID: 9128316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
    Rune SJ
    Scand J Gastroenterol Suppl; 1994; 205():45-7. PubMed ID: 7863241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the dyspeptic patient: a cost-utility study.
    Ebell MH; Warbasse L; Brenner C
    J Fam Pract; 1997 Jun; 44(6):545-55. PubMed ID: 9191627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
    Chen SY; Wang JY; Chen J; Zhang XD; Zhang SS
    J Gastroenterol Hepatol; 1999 Oct; 14(10):977-83. PubMed ID: 10530493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In search of the Holy Grail of Heliocobacter pylori remedies.
    Hopkins RJ
    Helicobacter; 2001 Jun; 6(2):81-3. PubMed ID: 11422461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A cost analysis of alternative treatments for duodenal ulcer.
    Imperiale TF; Speroff T; Cebul RD; McCullough AJ
    Ann Intern Med; 1995 Nov; 123(9):665-72. PubMed ID: 7574221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.
    Frampton JE; McTavish D
    Pharmacoeconomics; 1994 Jul; 6(1):57-89. PubMed ID: 10147354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer.
    Walan A; Eriksson S
    Scand J Gastroenterol Suppl; 1994; 201():91-7. PubMed ID: 8047832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan: a decision analysis to assess eradication strategy in comparison with a conventional strategy.
    Habu Y; Inokuchi H; Kiyota K; Hayashi K; Watanabe Y; Kawai K; Stålhammar NO
    J Gastroenterol Hepatol; 1998 Mar; 13(3):280-7. PubMed ID: 9570241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers.
    Sintonen H; Alander V
    J Health Econ; 1990 Jun; 9(1):85-101. PubMed ID: 10113227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibiotic therapy alone eradicates Helicobacter pylori and prevents duodenal ulcer recurrence.
    Laine L
    Gastroenterology; 1993 Aug; 105(2):598-9. PubMed ID: 8335215
    [No Abstract]   [Full Text] [Related]  

  • 52. Management of Helicobacter pylori in duodenal ulcer: a cost-effectiveness analysis.
    García-Altés A; Jovell AJ; Serra-Prat M; Aymerich M
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1631-8. PubMed ID: 11121912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease.
    Vakil N; Fennerty B
    Am J Med; 1996 May; 100(5A):60S-63S; discussion 63S-64S. PubMed ID: 8644784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of alternative medications in the treatment of duodenal ulcer.
    Ashton T
    Scand J Gastroenterol; 1991 Jan; 26(1):82-8. PubMed ID: 1900948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Omeprazole and ranitidine in duodenal ulcer healing. Analysis of comparative clinical trials.
    Mulder CJ; Schipper DL
    Scand J Gastroenterol Suppl; 1990; 178():62-6. PubMed ID: 2148984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Economic analysis of maintenance treatment with ranitidine 150 mg in duodenal ulcer].
    Ruszniewski P; Levy E; Mignon M
    Gastroenterol Clin Biol; 1992; 16(11):842-7. PubMed ID: 1483552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan.
    Perveen S; Gauhar S; Yousuf RI; Ali H; Zafar F; Sheikh AF
    PLoS One; 2022; 17(5):e0267791. PubMed ID: 35609024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis.
    Levy AR; Stock D; Paterson JM; Tamim H; Chateau D; Quail J; Ronksley PE; Carney G; Reynier P; Targownik L;
    CMAJ Open; 2023; 11(6):E1033-E1040. PubMed ID: 37935487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost effectiveness in Canada of a multidrug prepackaged regimen (Hp-PAC)+ for Helicobacter pylori eradication.
    Agro K; Blackhouse G; Goeree R; Willan AR; Huang JQ; Hunt RH; O'Brien BJ
    Pharmacoeconomics; 2001; 19(8):831-43. PubMed ID: 11596835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Benefits of treatment to eradicate Helicobacter pylori infection in patients with ulcer at a primary care center].
    Azagra Ledesma R; Gené Tous E; Bonet Simó JM; Solé Sancho F; Calvet Calvo X
    Aten Primaria; 2000 Apr; 25(6):377-82. PubMed ID: 10857226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.